Novità scientifiche — 6 Settembre 2026
Aggiornamenti scientifici verificati da MBC. Questa pagina contiene esclusivamente elementi acquisiti da fonti documentali tracciabili dopo il radar scientifico giornaliero. L’AI può indicare termini da controllare, ma il suo testo non viene pubblicato come fonte e non determina conclusioni cliniche.
Le informazioni sono presentate a fini documentali e non costituiscono una raccomandazione terapeutica, una previsione di efficacia o una valutazione di idoneità individuale.
Nuova documentazione
- Cationic amino acid-engineered radiopeptides for breast cancer targeting. · Agosto 16, 2026
PMID: 42612457 · DOI: 10.1016/j.bmc.2026.118780
Fonte documentale originale ↗ - First-in-Human Imaging Results of PHAROS: A Versatile High-Resolution TOF/DOI PET Scanner for Brain, Breast, and Extremity Imaging. · Agosto 3, 2026
PMID: 42209120 · DOI: 10.2967/jnumed.125.271172
Fonte documentale originale ↗ - Construction and application of mammary and breast cancer organoids · Ottobre 1, 2026
DOI: 10.1016/j.cellin.2026.100354
Fonte documentale originale ↗ - Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study · Marzo 1, 2025
DOI: 10.1016/j.esmorw.2024.100095
Fonte documentale originale ↗ - Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms. · Luglio 22, 2026
PMID: 42513228 · DOI: 10.3390/molecules31142551
Fonte documentale originale ↗ - The clinical value of the combined detection of circulating low ⁃ density neutrophils and inflammatory markers in breast cancer with lymph node metastasis · Giugno 23, 2026
DOI: 10.1186/s12885-026-16384-6
Fonte documentale originale ↗ - Over-presentation of apolipoprotein E gene variants E3/E4 and cardiovascular disease risk factors among Ghanaian breast cancer patients · Giugno 23, 2026
DOI: 10.1186/s12885-026-16354-y
Fonte documentale originale ↗ - Bioactive Imine-Amoxicillin Hybrids: Dual Antibacterial and Anti-Breast Cancer Potentials Supported by Molecular Docking · Giugno 30, 2026
DOI: 10.29409/2vpat285
Fonte documentale originale ↗ - ODAM: A Novel Tumor Suppressor Silenced in Breast Cancer · Giugno 30, 2026
DOI: 10.29409/k7h78q03
Fonte documentale originale ↗ - Highly Efficient Homologous Targeting Magnetic Resonance Imaging Probe for Enhanced T1 Contrast Imaging of Triple-Negative Breast Cancer by Deactivated Tumor Cell-Loaded Manganese Carbonate · Agosto 18, 2026
DOI: 10.1021/acsabm.6c00730
Fonte documentale originale ↗ - Comment on “Development and Evaluation of an Injectable Acellular Dermal Matrix for Breast Reconstruction” · Agosto 17, 2026
DOI: 10.1021/acsabm.6c00389
Fonte documentale originale ↗ - Legal Education and Informed Consent Quality among Mastectomy and Breast Reconstruction Patients: A Mixed-Methods Study · Agosto 25, 2026
DOI: 10.54518/rh.6.4.2026.1484
Fonte documentale originale ↗ - Hybrid CNN-RELM with Improved Butterfly Optimization Algorithm and Deep Adaptive Spatial Feature Fusion for Automated Breast Cancer Detection and Classification from Mammographic Images · Gennaio 1, 2026
DOI: 10.51483/ijaiml.6.8s.2026.271-281
Fonte documentale originale ↗ - PRECISION MEDICINE IN BREAST RECONSTRUCTION: CLINICAL ADVANCES, REHABILITATION AND PATIENT EDUCATION PERSPECTIVES · Dicembre 23, 2025
DOI: 10.31435/ijitss.4(48).2025.4501
Fonte documentale originale ↗ - Mechanistic Insights into Breast Cancer Targeting by 2-Oxo-2H-Chromene-7-yl 3-Methylbutanoate: An Integrated Computational Study · Settembre 7, 2026
DOI: 10.1007/s12247-026-10951-x
Fonte documentale originale ↗ - ACOD1 enhances the ferroptosis resistance of tumor-associated macrophages through the KEAP1/NRF2 axis and promotes triple-negative breast cancer progression · Novembre 1, 2026
DOI: 10.1016/j.prp.2026.156652
Fonte documentale originale ↗ - Resveratrol Nanoformulations for Cancer Management: A Comprehensive Review of Disease-Specific Strategies and Clinical Translational Barriers. · Luglio 28, 2026
PMID: 42542881 · DOI: 10.2147/ijn.s610050
Fonte documentale originale ↗ - Recent advances in metal-organic frameworks for the diagnosis and treatment of breast cancer. · Luglio 5, 2026
PMID: 42402086 · DOI: 10.1186/s11671-026-04710-7
Fonte documentale originale ↗ - MED1 in cancer: a context-dependent transcriptional regulator · Settembre 7, 2026
DOI: 10.1186/s12935-026-04457-2
Fonte documentale originale ↗ - NF-κB Inhibition Activity of Curcumin-Loaded Sterically Stabilized Micelles and Its Up-Regulator Effect on Enhancement of Cytotoxicity of a New Nano-Pirarubicin Formulation in the Treatment of Breast Cancer · Settembre 3, 2019
DOI: 10.25135/rnp.108.18.10.984
Fonte documentale originale ↗ - Evaluation of MCF-7 Breast Cancer Cell Cytotoxic and Antioxidant Activities of Peptide Fractions from Symbiotic Bacteria of Jellyfish Catostylus sp. · Gennaio 17, 2026
DOI: 10.33640/2405-609x.3442
Fonte documentale originale ↗
Biomarcatori e ricerca
- Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study · Marzo 1, 2025
DOI: 10.1016/j.esmorw.2024.100107
Fonte documentale originale ↗ - Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer · Giugno 18, 2026
DOI: 10.1038/s41598-026-57604-0
Fonte documentale originale ↗ - Copy number variants in BRCA1 and BRCA2 genes in Polish patients with breast and ovarian cancer · Giugno 23, 2026
DOI: 10.1007/s00432-026-06527-4
Fonte documentale originale ↗ - First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam · Settembre 7, 2026
DOI: 10.3389/fonc.2026.1871703
Fonte documentale originale ↗
Trial e studi clinici
- Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis. · Agosto 3, 2026
PMID: 42545662 · DOI: 10.1186/s11671-026-04831-z
Fonte documentale originale ↗ - Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32 · Aprile 30, 2026
DOI: 10.1093/jncics/pkag045
Fonte documentale originale ↗ - Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium · Gennaio 29, 2026
DOI: 10.1038/s41431-026-02014-z
Fonte documentale originale ↗
Farmaci e molecole
- Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. · Agosto 1, 2026
PMID: 42487497 · DOI: 10.1002/cncr.70544
Fonte documentale originale ↗ - Therapy-imprinted fibroblast memory in cholangiocarcinoma: rewiring CAF niches for immune evasion and treatment-resistant relapse. · Luglio 22, 2026
PMID: 42558642 · DOI: 10.3389/fimmu.2026.1907838
Fonte documentale originale ↗ - Sodium–glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk · Giugno 22, 2026
DOI: 10.1186/s12967-026-08473-8
Fonte documentale originale ↗ - Early-Stage Evaluation of a Novel Sexual Health Care Model for Breast Cancer Survivors Undergoing Endocrine Therapy: A Case Series · Settembre 6, 2026
DOI: 10.3390/nursrep16090324
Fonte documentale originale ↗ - Recent Progress in Exosome-Derived Nanocarriers for Breast Cancer Therapy: Advances, Translational Barriers, and Scale-Up Considerations. · Aprile 21, 2026
PMID: 42014584 · DOI: 10.1007/s11095-026-04095-3
Fonte documentale originale ↗ - Polyherbal Phytochemicals as Multi-Target Inhibitors of Key Breast Cancer Proteins: A Computational Approach · Marzo 12, 2026
DOI: 10.33640/2405-609x.3454
Fonte documentale originale ↗ - Enhancing photodynamic and chemodynamic therapy efficacy through a novel ROS-amplifying therapeutic platform for breast cancer treatment · Gennaio 1, 2026
DOI: 10.1039/d6nh00034g
Fonte documentale originale ↗ - Synthesis, biological evaluation, and DFT-based molecular modeling of novel Ni(II), Cu(II), and Co(II) complexes derived from a p-anisidine hydrazone for breast cancer therapy · Gennaio 1, 2027
DOI: 10.1016/j.molstruc.2026.147313
Fonte documentale originale ↗ - Discovery of novel indole-chalcone derivatives as potent hexokinase 2 inhibitors for triple negative breast cancer therapy · Ottobre 1, 2026
DOI: 10.1016/j.bioorg.2026.110310
Fonte documentale originale ↗ - Computer-aided drug design of quinoxaline based selective oestrogen receptor α modulators for breast cancer therapy: molecular docking, MD simulation, MM-PBSA and ADME/T analysis · Settembre 7, 2026
DOI: 10.1080/1062936x.2026.2719503
Fonte documentale originale ↗
Therapies complementari, alternative e repurposing
- Immune-associated alternative splicing signatures define molecular subtypes in breast cancer · Agosto 1, 2026
DOI: 10.1016/j.isci.2026.116732
Fonte documentale originale ↗
Metastasi ossee, vertebrali e radioligandi
- Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging · Luglio 21, 2026
DOI: 10.1021/acs.molpharmaceut.6c00242
Fonte documentale originale ↗